Research And Development

AstraZeneca

$51.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.34 (-4.30%) Today
-$0.35 (-0.67%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AstraZeneca and other stocks, options, and ETFs commission-free!

About AZN

AstraZeneca PLC American Depositary Shares, also called AstraZeneca, is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom. The listed name for AZN is AstraZeneca PLC American Depositary Shares.

CEO
Pascal Soriot
Employees
70,600
Headquarters
Cambridge, Cambridgeshire
Founded
1992
Market Cap
132.96B
Price-Earnings Ratio
56.35
Dividend Yield
2.54
Average Volume
13.58M
High Today
$53.40
Low Today
$52.04
Open Price
$53.37
Volume
14.55M
52 Week High
$64.94
52 Week Low
$36.15

Collections

AZN News

New York Times2h

Your Thursday Briefing

Europe’s coronavirus vaccination woes snowballed yesterday as Spain became the first country to partly suspend immunizations because of a lack of doses. Madrid
Reuters3h

AstraZeneca to produce 90 million COVID-19 vaccine shots in Japan - government spokesman

FILE PHOTO: A vial and sryinge are seen in front of a displayed AstraZeneca logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration T
Reuters5h

PRESS DIGEST- Financial Times - Jan. 28

Jan 28 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Head

AZN Earnings

$0.00
$0.33
$0.66
$0.99
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 11, Pre-Market

You May Also Like

STRT

More AZN News

MarketWatch8h

AstraZeneca PLC ADR falls Wednesday, underperforms market

The AstraZeneca PLC ADR AZN, -4.30% slid 4.30% to $52.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDA
MarketWatch12h

EU demands access to U.K.-made AstraZeneca vaccine shots as row over shortages intensifies

The row between AstraZeneca and the European Union intensified on Wednesday amid a shortage of vaccine doses in Europe. The EU’s health commissioner Stella Kyr
Reuters15h

Chilean health regulator approves AstraZeneca Covid-19 vaccine for emergency use

SANTIAGO, Jan 27 (Reuters) - Chile’s health regulator on Wednesday approved the AstraZeneca-Oxford COVID-19 vaccine for emergency use among its population by a
TIME16h

Call Between AstraZeneca and E.U. To Go Ahead Amid Blame-Game Over Vaccine Supply

The clash between the European Union and drugmaker AstraZeneca Plc over Covid-19 vaccine delays temporarily descended into chaos on Wednesday before the two sid
Reuters17h

South Africa approves AstraZeneca vaccine for emergency use

Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this
Reuters18h

AstraZeneca to ask Japan's JCR Pharmaceutical to produce COVID-19 vaccine - Nikkei

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S
Reuters19h

Raging virus, few shots. How Brazil missed its chance to secure COVID-19 vaccines

RIO DE JANEIRO (Reuters) - Weeks after other Latin American countries began inoculating their citizens against coronavirus, Brazil finally administered its firs
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure